monitoring the value of trial register information

38
MONITORING THE VALUE OF TRIAL REGISTER INFORMATION Thomson Pharmaceutical Services LAWRENCE LIBERTI MS, RPh, RAC JULY 16, 2008

Upload: talasi

Post on 13-Jan-2016

33 views

Category:

Documents


0 download

DESCRIPTION

MONITORING THE VALUE OF TRIAL REGISTER INFORMATION. Thomson Pharmaceutical Services LAWRENCE LIBERTI MS, RPh, RAC JULY 16, 2008. SCOPE OF TODAY’S PRESENTATION. PRACTICAL ROLE OF REGISTERS FORMATS OF REGISTER PRESENTATION METHODS TO ASSESS ONLINE REGISTER INFORMATION - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

MONITORING THE VALUE OF TRIAL REGISTER INFORMATIONThomson Pharmaceutical Services

LAWRENCE LIBERTI MS, RPh, RACJULY 16, 2008

Page 2: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

2

SCOPE OF TODAY’S PRESENTATION

• PRACTICAL ROLE OF REGISTERS

• FORMATS OF REGISTER PRESENTATION

• METHODS TO ASSESS ONLINE REGISTER INFORMATION

• DETERMINING THE VALUE OF REGISTERS TO TARGET USERS

• CONCLUSIONS

Page 3: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

REGISTER vs REGISTRY?

Page 4: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

4

WHAT’S IN A NAME?

• Registry: A repository of ongoing clinical trials– www.clinicaltrials.gov

– “Clinical Trial Registry Data Bank” (FDAAA)

• Register: A repository for the results of clinical trials– www.clinicalstudyresults.org

– “Results Data Bank” (FDAAA)

Page 5: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

THE PRACTICAL ROLE OF REGISTRIES and REGISTERS

Page 6: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

6

REGULATORY INITIATIVES

• State Bills (to amend the PHS Act to expand the clinical trials drug data bank)

• *******FDAAA September 2008 Title VIII- Clinical Trial Databases********

Page 7: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

7

The Maine Precedent

• Maine law requires manufacturers or labelers of prescription drugs to list information on clinical trials on prescription drugs that have been FDA-approved for marketing and are (or have been) dispensed, administered, delivered or promoted in Maine. Certain registration and results information must be posted on clinical trials conducted or sponsored by the manufacturer on or after October 15, 2002. The date by which the information must be posted varies depending on when the trial occurred and when the drug first enters Maine.

An Act Regarding Advertising by Drug Manufacturers and

Disclosure of Clinical Trials

Page 8: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

8

Page 9: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

9

THE PRACTICAL ROLE OF REGISTRIES

• For federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. (Sponsored by US National Institutes of Health)

Page 10: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

10

THE PRACTICAL ROLE OF REGISTERS

• The ClinicalStudyResults.org site is a central, widely accessible, web-based repository for clinical study results in a reader-friendly, standardized format. This database will serve the valuable function of making clinical trial results for many marketed pharmaceuticals more transparent. More importantly, it is designed as a key tool to provide information to practicing physicians and their patients. (Sponsored by PhRMA)

Page 11: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

FORMATS OF PRESENTATIONS

Study ListingsResults Postings

Page 12: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

12

STUDY LISTINGS (www.clinicaltrials.gov)

• ClinicalTrials.gov currently has 58,702 trials with locations in 157 countries

Page 13: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

13

Page 14: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

14

Page 15: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

15

RESULTS POSTINGS

• Welcome to ClinicalStudyResults.org!

• The ClinicalStudyResults.org site is a central, widely accessible, web-based repository for clinical study results in a reader-friendly, standardized format. This database will serve the valuable function of making clinical trial results for many marketed pharmaceuticals more transparent. More importantly, it is designed as a key tool to provide information to practicing physicians and their patients.

Page 16: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

16

SUMMARY OF THE ROLE OF RESULTS POSTINGS

• To provide a repository of information

• To provide a balanced overview of clinical study-derived information

• To comply with regulatory requirements

• NOT intended to promote off-label uses

• NOT intended to provide conclusions

Page 17: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

17

WYETH-SPONSORED STUDY

Page 18: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

18

GSK APPROACH TO SUMMARY FORMATS

Page 19: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

19

Page 20: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

20

Page 21: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

21

AVANDIA P-1 ONLINE REPORT (GSK)

Page 22: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

22

No Conclusions

Page 23: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

23

LILLY-SPONSORED STUDY

Page 24: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

24

Page 25: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

25

Page 26: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

26

Page 27: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

METHODS TO ASSESS REGISTER INFORMATION

Page 28: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

28

METHODS TO ASSESS REGISTER INFORMATION

Page 29: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

29

METHODS TO ASSESS REGISTER INFORMATION

Page 30: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

30

Page 31: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

DETERMINING THE VALUE OF REGISTERS TO TARGET USERS

Page 32: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

32

DETERMINING THE VALUE OF REGISTERS TO TARGET USERS RAISES MANY QUESTIONS

• How will health professionals use register information?– As a primary source of data?

– As a back-up to published data

• How will consumers use the information?

• What will drive users to registers?

• What will users remember from registers?

• Will register data impact knowledge and drug use?

Page 33: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

33

UAB STUDY RESULTS

• Designed to assess how physicians use medical literature to learn about drug therapies

• CME-accredited program through University of Alabama School of Medicine

• N = 299 physicians– IM, FP, GP specialties

– Urban, suburban, rural practices

– 1 to > 20 years since medical school

Liberti L, Casebeer L, et al: Critical appraisal of medical literature by physicians and its relevance to practice. Presented at the 64th Annual Conference of the American Medical Writers Association, St. Louis, MO, October 2004.

Page 34: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

34

THE UAB STUDY RESULTS

• How much time do you spend reading scientific literature each week?

1-2 hrs 30%

3-4 hrs 35%

5-6 hrs 15%

6-8 hrs 10%

>8 hrs 10%

• 65% spent up to 4 hrs reading literature

Page 35: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

35

CONCLUSIONS

• Clinicians read in limited time, so information must be positioned:– To a target audience

– To have an impact on a thought process

– With good information concentrated in specific areas of the article

– With clear messages supported by data

Page 36: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

36

INFERENCES FOR TRIAL REGISTERS

• Clinicians have limited time to access and interpret the information

• Clinicians can distinguish between “solid” and “weak” clinical reports

• Simplify the data presentation structure, length

• Provide valid information

• How can conclusions be drawn without regulatory conflicts?

• Need to validate new tools to assess the practical value and impact of register information

Page 37: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

37

HOW CAN THOMSON REUTERS HELP?

– Custom information solutions

– Regulatory support

– Decision-making support

– Database development

– Content/editorial support

Page 38: MONITORING THE VALUE OF TRIAL REGISTER INFORMATION

38

COMPETITORS?• TrialTrove (www.citeline.com)

• ADIS Clinical Trials Insight

• Espicom Pharma & Med Device News

• FDA News: Drug Pipeline Alert

• IMS R&D Focus, New Drugs

• IDIS InPharma

• NewsRx

• PHIND

• PROMT

• Prous Daily Essentials

• Scrip

• Controlledtrials.com

• The Clinical Trial Registry Platform (www.who.int/ictrp/en)

• Centerwatch (centerwatch.com)

Snow B: Previewing clinical trial results online. November 2005

Liberti L et al: In Search of “Clinical Trial register Version 2.0” in Clinical Trial Registries: A practical Guide for Sponsors and Researchers of Medicinal Products.